Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Method for treating lupus by administering an anti-IL-12 antibody
US10519231B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10519231-B2 |
| Application number | US-201916284316-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 25, 2019 |
| Priority date | Aug 7, 2000 |
| Publication date | Dec 31, 2019 |
| Grant date | Dec 31, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for reducing symptoms of systemic lupus erythematosus in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region of the amino acid sequence of SEQ ID NO: 8, intravenously to said animal. 2. The method according to claim 1 , wherein said effective amount is 0.001-50 mg/kilogram of said animal. 3. The method according to claim 1 , further comprising administering at least one composition comprising an effective amount of a cytokine antagonist. 4. A method for reducing symptoms of systemic lupus erythematosus in an animal, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain complementarity determining region CDR 1 of the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 of the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR3 of the amino acid sequence of SEQ ID NO: 3, a light chain CDR1 of the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 of the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 of the amino acid sequence of SEQ ID NO: 6, intravenously to said animal. 5. The method according to claim 4 , wherein said effective amount is 0.001-50 mg/kilogram of said animal. 6. The method according to claim 4 , further comprising administering at least one composition comprising an effective amount of a cytokine antagonist. 7. A method for reducing symptoms of systemic lupus erythematosus in a human, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region of the amino acid sequence of SEQ ID NO: 8, intravenously to said human. 8. The method according to claim 7 , wherein said effective amount is 0.001-50 mg/kilogram of said human. 9. The method according to claim 7 , further comprising administering at least one composition comprising an effective amount of a cytokine antagonist. 10. A method for reducing symptoms of systemic lupus erythematosus in a human, comprising administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain complementarity determining region CDR 1 of the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 of the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR3 of the amino acid sequence of SEQ ID NO: 3, a light chain CDR1 of the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 of the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 of the amino acid sequence of SEQ ID NO: 6, intravenously to said human. 11. The method according to claim 10 , wherein said effective amount is 0.001-50 mg/kilogram of said human. 12. The method according to claim 10 , further comprising administering at least one composition comprising an effective amount of a cytokine antagonist.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunostimulants · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10519231B2 cover?
- Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).